PI Industries Health Sciences Loss Continues Despite Q2 Growth

PI Industries’ Health Sciences business increased Q2FY27 revenue 20% year on year to Rs 75.9 crore but reported a Rs 63.3 crore loss before tax, or PBT, after intercompany eliminations. The quarterly loss was Rs 2.1 crore lower than a year earlier, while H1FY27 revenue fell 4% and the half-year loss widened.

Why did PI Health Sciences remain loss-making in Q2FY27?

PI Health Sciences remained loss-making because its Q2FY27 PBT was a loss of Rs 63.3 crore despite revenue of Rs 75.9 crore. The presentation does not provide a cost breakdown or identify a specific cause of the loss. It does disclose investment in infrastructure, development and manufacturing capacity, as well as work on products intended for long-term contracts.

The quarterly result improved against Q2FY26 in two reported respects. Revenue increased by Rs 12.5 crore from Rs 63.4 crore, while the PBT loss reduced by Rs 2.1 crore from Rs 65.4 crore. Both sets of figures are presented after intercompany eliminations, meaning transactions within the group have been removed from the reported Health Sciences result.

How did PI Health Sciences perform in H1FY27?

PI Health Sciences reported H1FY27 revenue of Rs 130.1 crore, down 4% from Rs 135.7 crore in H1FY26, while its PBT loss widened to Rs 125 crore from Rs 123.6 crore. The first-half comparison differs from the Q2 trend, which showed higher revenue and a narrower loss against the prior-year quarter.

Q2FY27 revenue of Rs 75.9 crore accounted for more than half of H1FY27 revenue of Rs 130.1 crore. The presentation does not provide separate Q1 figures or explain the movement between the two quarters. The disclosed data shows that the Q2 improvement did not reverse the decline in first-half revenue or the Rs 1.4 crore increase in the half-year PBT loss.

What infrastructure is PI building for Health Sciences?

PI is building Health Sciences infrastructure through a Kilo Lab plant in Lodi, Italy, and a research and development, or R&D, centre in Hyderabad. The company presents both facilities as investments for future growth and also lists Jaipur in the Health Sciences section, without a separate operating or financial disclosure for that location.

The Lodi site has received AIFA GMP certification and Quality Control Lab GMP certification, according to the presentation. Good Manufacturing Practice, or GMP, certification is disclosed as a site qualification, while the financial data shows the business continued to report a PBT loss in Q2FY27. PI also says Lodi infrastructure is entering a mature phase, but does not state a completion date, capital-spending amount, capacity or expected revenue contribution.

What customer opportunities has PI disclosed?

PI says it has onboarded marquee customers, including large pharmaceutical companies, and is working on two strategic products for long-term contracts. The presentation does not identify the customers or products, nor does it disclose contract values, contract timing or expected commercial volumes.

Management says deeper customer engagement is showing “some early shoots” and describes the effort as part of a differentiated business model. This is a management characterisation of progress rather than a profitability forecast. The Rs 75.9 crore of Q2FY27 revenue confirms that the unit has sales, but the Rs 63.3 crore PBT loss indicates that reported sales did not yet produce positive PBT on the stated basis.

The two strategic products matter because PI specifically connects them to potential long-term contracts. However, the company has not set a target for the number of contracts, a margin objective or a break-even date. The disclosures distinguish confirmed activity, including customer onboarding and product work, from outcomes that have not yet been quantified, such as contract conversion and capacity utilisation.

What is PI’s stated plan for the Health Sciences business?

PI’s stated plan is to build a differentiated Health Sciences model through customer engagement, dedicated development and manufacturing capacity, and strategic products for long-term contracts. The presentation identifies Health Sciences as one of PI’s emerging opportunity areas, alongside agriculture, horticulture and biologicals.

For Health Sciences, the operating evidence cited by PI is the Lodi Kilo Lab, the Hyderabad R&D centre, Lodi certifications and engagement with pharmaceutical customers. PI does not provide FY27 revenue guidance, PBT guidance or a profitability timetable for the unit. Its statement that Lodi infrastructure is moving towards a mature phase is the principal disclosed operational milestone.

The presentation gives its export business an expectation of commercialising more than five products in FY27, but provides no comparable Health Sciences product-commercialisation target. That difference limits comparison of near-term milestones across businesses. For Health Sciences, financial updates will show whether the reported investment, certification and customer-engagement work change the revenue and loss pattern.

Conclusion

PI Health Sciences reported a mixed financial picture in the periods disclosed. Q2FY27 revenue rose 20% and the PBT loss narrowed by Rs 2.1 crore, but H1FY27 revenue declined 4% and the half-year PBT loss increased by Rs 1.4 crore. The presentation positions the business as a developing platform supported by facilities, certifications and customer work rather than one that has reached reported profitability.

The next disclosed items to watch are the maturation of Lodi infrastructure and progress on the two strategic products intended for long-term contracts. PI has not disclosed a Health Sciences profitability target, contract value, capacity figure or completion date, so future financial reporting and updates on contract conversion remain the stated plan’s measurable indicators.